¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾ÖÅú×¼ng28ÄϹ¬¿¹°©Ò©°¬Á¢²¼ÁÖÓÃÓÚÖÎÁƾֲ¿ÍíÆÚ»òתÒÆÐÔÈéÏÙ°©

ng28ÄϹ¬Öêʽ»áÉ磨×ܲ¿Î»ÓÚÈÕ±¾¶«¾©£¬ÏÖÈÎÉ糤ΪÄÚÌÙÇç·ò£¬ÒÔϼò³Æ¡°ng28ÄϹ¬¡±£©Ðû²¼£¬Öйú¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾ÖÒÑÅú×¼ng28ÄϹ¬Ô­Ñп¹°©Ò©¼×»ÇËá°¬Á¢²¼ÁÖ£¨º£ÀÖÎÀ?£©ÉÏÊУ¬ÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýÖÁÉÙÁ½ÖÖ»¯ÁƼƻ®£¨°üÀ¨Ýì»·ÀàºÍ×ÏɼÀࣩÖÎÁƵľֲ¿¸´·¢»òתÒÆÐÔÈéÏÙ°©»¼Õß¡£

¸ÃÅú×¼»ùÓÚ3041Ñо¿µÄ½á¹û£¬Ò»Ïî¶àÖÐÐÄ¡¢¿ª·ÅÐÔ¡¢Ëæ»ú¡¢Æ½ÐбÈÕÕµÄIIIÆÚÁÙ´²Ñо¿£¬Ö¼ÔÚÆÀ¼Û°¬Á¢²¼Áֺͳ¤´ºÈð±õ¶Ô530Àý¾Ö²¿¸´·¢»òתÒÆÐÔÈéÏÙ°©Å®ÐÔ»¼ÕßµÄÁÆЧ¼°Äþ¾²ÐÔ£¬´ËÀ໼Õß¼ÈÍùÒѽÓÊÜ°üÀ¨Ýì»·ÀàºÍ×ÏɼÀàÔÚÄڵĻ¯ÁƼƻ®¡£ÔÚÕâÏîÑо¿ÖУ¬Æ¾¾Ý¶ÀÁ¢Ó°ÏñѧÉó²é£¨HR: 0.80; 95%?CI: 0.65-0.98; p<0.036£©ÏÔʾ£¬Ó볤´ºÈð±õ±ÈÕÕÖÎÁÆ×éÏà±È£¬°¬Á¢²¼ÁÖÖÎÁÆ×éµÄÖ÷ÒªÖյ㣬¼´ÎÞ½øÕ¹Éú´æÆÚ£¨PFS£©ÊµÏÖÁËͳ¼ÆѧÏÔÖøµÄÑÓ³¤¡£

°¬Á¢²¼ÁÖ×éÊӲ쵽Îå¸ö×î³£¼ûµÄ²»Á¼Ê¼þΪ£º°×ϸ°û¼ÆÊý½µµÍ¡¢ÖÐÐÔÁ£Ï¸°û¼ÆÊý½µµÍ¡¢ÌìÃŶ¬°±Ëá°±»ùתÒÆøÉý¸ß¡¢±û°±Ëá°±»ùתÒÆøÉý¸ßÒÔ¼°Æ¶Ñª£¬´ËÀàʼþÓë°¬Á¢²¼ÁÖµÄÒÑÖª¸±×÷ÓÃÒ»Ö¡£

ÔÚÖйú£¬±»Õï¶ÏΪÈéÏÙ°©µÄÅ®ÐÔÈËÊý½üÄêÀ´ÓÐËùÔö¼Ó2£¬ÈéÏÙ°©ÒѳÉΪÖйúÅ®ÐÔÕï¶Ï¸ß·¢°©Ö¢Ö®Ò»¡£3

°¬Á¢²¼ÁÖÊÇÒ»ÖÖÈíº£ÃàËØÀà΢¹Ü¶¯Á¦Ñ§ÒÖÖƼÁ£¬¾ßÓÐÆæÌصĽáºÏÌØÐÔ¡£³ýÁ˹ŰåµÄ×÷ÓûúÖÆÍ⣬ÌåÍâÑо¿ÏÔʾÁË°¬Á¢²¼ÁÖ¶ÔÖ×Áö΢Çé¿öµÄÆæÌØ×÷Óã¬ÀýÈ磺Ôö¼ÓÖ×Áö½¹µãµÄѪ¹Ü¹à×¢ºÍͨ͸ÐÔ4£¬Ôö½øÉÏƤ״̬£¬½µµÍÈéÏÙ°©Ï¸°ûµÄǨÒÆÄÜÁ¦µÈ5¡£Ä¿Ç°£¬°¬Á¢²¼ÁÖÒÑÔÚ°üÀ¨Å·ÖÞ¡¢ÃÀÖÞºÍÑÇÖÞÔÚÄÚµÄ65¸ö¹ú¼ÒºÍµØÇø»ñµÃÅú×¼£¬ÓÃÓÚÈéÏÙ°©µÄÖÎÁÆ¡£

ng28ÄϹ¬½«Ö×ÁöÁìÓò¶¨Î»ÎªÒ»¸öÒªº¦µÄÖÎÁÆÁìÓò£¬Ö¼ÔÚ·¢Ã÷¾ßÓÐÖÎÓú°©Ö¢Ç±Á¦µÄ¸ïÃüÐÔÐÂÒ©Îï¡£×Ô2018Äê11ÔÂÒÔÀ´£¬ÀÖÎÀÂê?ÔÚÖйú»ñÅúÓÃÓÚÖÎÁÆδ½ÓÊܹýÈ«ÉíÖÎÁÆÇÒ»¼Óв»¿ÉÇгý¸Îϸ°û°©µÄ»¼Õß¡£¼Ì°¬Á¢²¼ÁÖ»ñÅúºó£¬ng28ÄϹ¬½«ÖÂÁ¦ÓÚÖ§¸¶¸ü´óŬÁ¦ÒÔÂú×ã°©Ö¢»¼Õß¼°Æä¼ÒÈËÒÔ¼°Ò½ÁƱ£½¡ÌṩÕߵĶàÑù»¯ÐèÇó£¬Ìá¸ßÆ丣ìí¡£

ýÌå×Éѯ£º
ng28ÄϹ¬Öêʽ»áÉç
¹«¹²¹Øϵ²¿
+81-(0)3-3817-5120


¡¾±àÕß°´¡¿
1.¹ØÓÚ¼×»ÇËá°¬Á¢²¼ÁÖ
°¬Á¢²¼ÁÖÊÇÒ»ÖÖÈíº£ÃàËØÀà΢¹Ü¶¯Á¦Ñ§ÒÖÖƼÁ£¬¾ßÓÐÐÂÐ͵Ä×÷ÓûúÖÆ¡£´Ó½á¹¹ÉÏÀ´Ëµ£¬°¬Á¢²¼ÁÖΪÈíº£ÃàËØB¼ò»¯¼°ºÏ³ÉµÄ°æ±¾¡£Èíº£ÃàËØBΪ´Óº£ÃࣨÐþÉ«Èíº£ÃࣩÖÐÊèÉ¢³öµÄÒ»ÖÖÌìÈ»²úÆ·¡£°¬Á¢²¼ÁÖ±»ÈÏΪͨ¹ýÒÖÖÆ×èֹϸ°ûÆÆÁѵÄ΢¹Ü¶¯Á¦Ñ§µÄÉúºã¾Ã·¢»Ó×÷ÓᣱðµÄ£¬·ÇÁÙ´²Ñо¿ÏÔʾÁË°¬Á¢²¼ÁÖÔÚÖ×Áö΢Çé¿öÖеÄÆæÌØ×÷Óã¬ÈçÔö¼ÓÖ×Áö½¹µãÇøÓòµÄѪ¹Ü¹à×¢ºÍÉø͸ÐÔ4£¬¸ÄÉÆÉÏƤϸ°û״̬£¬½µµÍÈéÏÙ°©Ï¸°ûµÄǨÒÆÄÜÁ¦µÈ5¡£

2010Äê11Ô£¬°¬Á¢²¼ÁÖÔÚÃÀ¹úÊ״λñÅúÓÃÓÚÖÎÁÆתÒÆÐÔÈéÏÙ°©»¼Õß¡£Ä¿Ç°£¬°üÀ¨Å·ÖÞ¡¢ÃÀÖÞºÍÑÇÖÞ£¬Áè¼Ý65¸ö¹ú¼ÒºÍµØÇøÅú×¼°¬Á¢²¼ÁÖÓÃÓÚÖÎÁÆÈéÏÙ°©¡£±ðµÄ£¬°¬Á¢²¼ÁÖÓÚ2016Äê1ÔÂÔÚÃÀ¹úÊ״α»Åú×¼ÓÃÓÚÖÎÁÆÈí×éÖ¯ÈâÁö£¬ËæºóÔÚ55¸ö¹ú¼ÒºÍµØÇø»ñµÃÅú×¼¡£Í¬Ê±£¬°¬Á¢²¼ÁÖÒÑÔÚÃÀ¹úºÍÈÕ±¾±»È϶¨ÎªÖÎÁÆÈí×éÖ¯ÈâÁöµÄ¹Â¶ùÒ©¡£

¾ßÌåÀ´Ëµ£¬°¬Á¢²¼ÁÖ»ñÅúÒÔÏÂÊÊÓ¦Ö¢£º

ÔÚÃÀ¹ú£¬ÓÃÓÚÖÎÁÆ£º

  • ¼ÈÍùÒòΪתÒÆÐÔ¼²²¡ÖÎÁƶø½ÓÊÜÖÁÉÙÁ½ÖÖ»¯ÁƼƻ®µÄתÒÆÐÔÈéÏÙ°©»¼Õß¡£¼ÈÍùÖÎÁÆÓ¦°üÀ¨¸¨Öú»òתÒÆÐÔ¼²²¡Å侰ϵÄÝì»·ÀàÒ©ÎïºÍ×ÏɼÀà¡£
  • ¼ÈÍù½ÓÊܹýº¬Ýì»·ÀàÒ©ÎïÖÎÁƵIJ»¿ÉÇгý»òתÒÆÐÔÖ¬·¾ÈâÁö»¼Õß¡£

ÔÚÈÕ±¾£¬ÓÃÓÚÖÎÁÆ£º

  • ²»¿ÉÊÖÊõµÄ»ò¸´·¢ÐÔÈéÏÙ°©»¼Õß
  • Èí×éÖ¯ÈâÁö»¼Õß

ÔÚÅ·ÖÞ£¬ÓÃÓÚÖÎÁÆÒÔϳÉÄ껼Õߣº

  • ¼ÈÍù½ÓÊܹýº¬Ýì»·ÀàÒ©ÎïÖÎÁÆÍíÆÚ¼²²¡µÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔÈéÏÙ°©»¼Õß¡£¼ÈÍùÖÎÁÆÓ¦°üÀ¨¸¨Öú»òתÒÆÐÔ¼²²¡Å侰ϵÄÝì»·ÀàÒ©ÎïºÍ×ÏɼÀ࣬³ý·Ç»¼Õß²»ÊʺϽÓÊÜÕâЩÖÎÁÆ¡£
  • ¼ÈÍù½ÓÊܹýº¬Ýì»·ÀàÒ©ÎïÖÎÁÆ£¨³ý·Ç²»ÊÊÓã©ÍíÆÚ»òתÒÆÐÔ¼²²¡µÄ²»¿ÉÇгýÖ¬·¾ÈâÁö»¼Õß¡£

2.¹ØÓÚÑо¿3041

ÔÚÖйú½øÐеÄ304Ñо¿ÊÇÒ»Ïî¶àÖÐÐÄ¡¢¿ª·ÅÐÔ¡¢Ëæ»ú¡¢Æ½ÐбÈÕÕµÄIIIÆÚÁÙ´²Ñо¿£¬Ö¼ÔÚÆÀ¼Û°¬Á¢²¼Áֺͳ¤´ºÈð±õ¶Ô530Àý¾Ö²¿¸´·¢»òתÒÆÐÔÈéÏÙ°©Å®ÐÔ»¼ÕßµÄÁÆЧ¼°Äþ¾²ÐÔ£¬´ËÀ໼Õß¼ÈÍùÖÁÉÙ½ÓÊܹýÁ½ÖÖ²¢ÇÒ×î¶àÎåÖÖ»¯ÁƼƻ®µÄÖÎÁÆ£¨°üÀ¨Ýì»·ÀàºÍ×ÏɼÀࣩ¡£»¼Õßÿ21ÌìÒ»¸öÁƳÌ£¬½ÓÊÜ°¬Á¢²¼ÁÖ£¨¶Ô264Ãû»¼ÕßÔÚµÚ1ÌìºÍµÚ8ÌìÒÔ1.4mg/m2ͨ¹ý¾²Âö¸øÒ©£©»ò³¤´ºÈð±õ£¨¶Ô266Ãû»¼ÕßÔÚµÚ1Ìì¡¢µÚ8ÌìºÍµÚ15ÌìÒÔ25 mg/m2ͨ¹ý¾²Âö¸øÒ©£©ÖÎÁÆ¡£Ñо¿µÄÖ÷ÒªÖÕµãΪÎÞ½øÕ¹Éú´æÆÚ£¨PFS£©¡£

1?Yuan P et al., Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomized clinical trial?Eur J Cancer,?2019; 112, 57-65
2?Lei F et al., Breast cancer in China.?The Lancet Oncology,?2014; 15(7), e279¨Ce289
3?Ferlay J, et al., (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.?https://gco.iarc.fr/today, As of July 17, 2019??
4?Funahashi Y et al., Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.?Cancer Sci.,?2014; 105, 1334-1342
5?Yoshida T et al., Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer, 2014; 110, 1497-1505